Dalbavancin U.S. approval delay
Partner's U.S. launch delayed due to additional data request; approval expected in February but uncertainty remains.
medium · analyst_questionGland Pharma Limited — Q3 FY26
Gland Pharma delivered a strong Q3 FY26 with consolidated revenue of INR 1,695.4 crore (+22% YoY) and adjusted EBITDA of INR 449 crore (+25% YoY), driven by broad-based growth a...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Cenexi quarterly volatility
Management acknowledged quarter-to-quarter fluctuations at Cenexi, which could impact near-term consolidated results.
medium · management_commentaryGLP-1 capacity utilization risk
Despite expanding cartridge capacity, management is conservative on GLP-1 revenue, citing patent and pricing uncertainties.
medium · management_commentaryCDMO contract ramp-up slower than expected
New CDMO contracts (e.g., oncology) start only by end-2028, with meaningful revenue contribution delayed.
low · data_observation